Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

Merck hits 'go' on a second Dragonfly drug

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

AbbVie selects target for Dragonfly partnership

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer

Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy

Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

A booming Dragonfly is taking its TriNKETs to Copenhagen